ArticlePharmacology, biochemistry, and behavior2011
Disparate effects of pramipexole on locomotor activity and sensorimotor gating in Sprague-Dawley rats.
Article in Pharmacology, biochemistry, and behavior, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 25 citations in OpenAlex.
- Aberrant striatal firing mediates impulsive decision-making in a mouse model of Parkinson's disease.Brain : a journal of neurology · 2026Article
- Pramipexole restores behavioral inhibition in highly impulsive rats through a paradoxical modulation of frontostriatal networks.Translational psychiatry · 2024Article
- Antioxidant Behavioural Phenotype in theGenes · 2023Article
- Premorbid performances determine the deleterious effects of nigrostriatal degeneration and pramipexole on behavioural flexibility.NPJ Parkinson's disease · 2023Article
- The adverse effects of pramipexole on probability discounting are not reversed by acute DEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2020Article
- Effects of pramipexole on the acquisition of responding with opioid-conditioned reinforcement in the rat.Psychopharmacology · 2015Article
- MitoPark mice, an animal model of Parkinson's disease, show enhanced prepulse inhibition of acoustic startle and no loss of gating in response to the adenosine A(2A) antagonist SCH 412348.Psychopharmacology · 2014Article
- Chronic pramipexole treatment increases tolerance for sucrose in normal and ventral tegmental lesioned rats.Frontiers in neuroscience · 2014Article
- Dopamine D3 and 5-HT1B receptor dysregulation as a result of psychostimulant intake and forced abstinence: Implications for medications development.Neuropharmacology · 2014Review
- Pramipexole-induced disruption of behavioral processes fundamental to intertemporal choice.Journal of the experimental analysis of behavior · 2013Article
- Effects of the 5HT2C antagonist SB242084 on the pramipexole-induced potentiation of water contrafreeloading, a putative animal model of compulsive behavior.Psychopharmacology · 2013Article
- Inhibition of 50-kHz ultrasonic vocalizations by dopamine receptor subtype-selective agonists and antagonists in adult rats.Psychopharmacology · 2013Article
- Stereochemical and neuroanatomical selectivity of pramipexole effects on sensorimotor gating in rats.Brain research · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Prepulse inhibition (PPI) of acoustic startle and locomotor activity are both widely studied in the preclinical development of dopaminergic agents, including those acting at D3 dopamine receptors. In mice, the dopamine D3 receptor-preferential agonist pramipexole (PPX) alters locomotor activity in a biphasic manner at doses that have no effect on PPI. The present study examined the time-course of PPX effects on locomotion and PPI in rats. In adult male Sprague-Dawley rats, PPX (0, 0.1, 0.3, 1.0mg/kg) was injected prior to measurement of locomotor activity for 90 min in photobeam chambers. Based on disparate early vs. late effects of PPX on locomotion, the effects of PPX (0 vs. 0.3mg/kg) on PPI were tested 20 and 80 min after injection. All doses of PPX decreased locomotor activity for 30 min compared to vehicle, and the higher doses stimulated hyperlocomotion later in the session; the late hyperlocomotion, but not the early hypolocomotion, was blocked by the D2-selective antagonist, L741626 (1.0mg/kg sc). In contrast to its locomotor effects, PPX caused a similar reduction in PPI at 20 and 80 min after administration. These findings suggest both a temporal and pharmacological dissociation between PPX effects on locomotor activity and PPI; these two behavioral measures contribute non-redundant information to the investigation of D3-related behavioral pharmacology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.